Skip to main content
European Commission logo print header

An innovative topical drug delivery system for improving chronic wound healing

Project description

Chronic wound therapy in a tube will soon promote healing safely, simply and effectively

Chronic wounds represent a significant socioeconomic burden impacting patients and healthcare systems. This burden is likely to increase given a growing proportion of elderly people and an increasing prevalence of lifestyle-related diseases such as cancer and diabetes. Improved treatments are desperately needed to avoid potentially devastating consequences. The Swiss company Stratpharma has developed a range of topical gel-based film-forming wound dressings that are also able to deliver drugs to the wound to promote healing. With EU funding of the StrataGRT project, the team is enhancing their proprietary formulation for application to chronic wounds. The project will enable product finalisation as well as scaling up of manufacturing processes and a comprehensive business plan to get it to patients quickly.

Objective

Skin is the largest organ in the human body, forming a protective physical barrier against the outside world. Damages to skin due to physical, chemical and biological factors lead to wounds. While minor wounds heal on their own, chronic wounds (wounds that do not heal within 8 weeks), such as diabetic foot ulcers, subject the patient to significant discomfort and distress while draining the medical system of an enormous amount of resources. Wound healing is a complex, highly regulated process, and complications affect the quality of life of >4 million a year in EU (more than cancer & diabetes) that struggle to live with hard-to-heal injuries, as it can lead to infection, tissue and bone necrosis, pain and in some severe cases even amputation. Stratpharma has developed a range of primary dressings formulated as a silicone-based gel, which can be used on any wounded, damaged, compromised or diseased skin surface. This proprietary film-forming gel is also shown to be an excellent drug delivery system, using which active compounds can be delivered to the wound, thereby enhancing clinical outcomes. Using this property, Stratpharma aims to develop a breakthrough formulation, containing gel and bioglass technology, for improved chronic wound healing. During the phase 1 project, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. Within the overall innovation project, Stratpharma will further test and validate the new formulation, begin clinical trials, implement IP strategy and perform scaling-up activities.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Coordinator

STRATPHARMA AG
Net EU contribution
€ 50 000,00
Address
AESCHENVORSTADT 57
4051 BASEL
Switzerland

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Schweiz/Suisse/Svizzera Nordwestschweiz Basel-Stadt
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 71 429,00